GE‘s SenoBright technology that reconstructs mammography images taken using two different energy ranges of X-rays just obtained FDA approval. Also known as Contrast Enhanced Spectral Mammography (CESM), the system relies on an injected X-ray contrast agent and two separate but almost simultaneous exposures that together provide enough data to potentially pinpoint otherwise hard to spot tumors.
SenoBright can be installed as an additional option on previously purchased GE Senographe DS and Senographe Essential digital mammography systems.
Press release: GE Healthcare Announces FDA 510(k) Clearance of SenoBright Contrast Enhanced Spectral Mammography (CESM) for Breast Cancer Diagnosis …
Product page: Contrast Enhanced Spectral Mammography …
Flashback: GE Launches SenoBright Contrast Enhanced Spectral Mammography